Loading...
Although recent changes in screening guidelines have been broadly promulgated, an estimated 233,000 men will be diagnosed with prostate cancer this year, and the vast majority will have clinically organ-confined disease. Many of these men will undergo curative-intent local therapy (surgery and radiotherapy), but substantial numbers will receive primary androgen-deprivation therapy (ADT), despite the absence of data to support its use in this setting.
To provide additional insight into the utility of ADT for patients with early-stage prostate cancer, investigators performed a population-based cohort study involving 66,717 Medicare patients (66 or older) in the Surveillance, Epidemiology, and End Results (SEER) program database who were diagno…